Drug use screening is a structured way for healthcare professionals to ask about substance use, identify possible risks, and decide whether a person needs brief counseling, closer assessment, medical care, or treatment for a substance use disorder. It is not meant to shame people, label them, or replace a full clinical evaluation.
In a brain, cognitive, or mental health workup, substance use screening can be especially important because drugs, nonmedical prescription medication use, withdrawal, and intoxication can affect mood, sleep, attention, memory, anxiety, psychosis-like symptoms, and physical safety. A good screening process is private, nonjudgmental, and practical: it helps clinicians understand what is happening and what kind of support would be most useful.
Table of Contents
- What Drug Use Screening Means
- When Doctors Screen for Drug Use
- Common Drug Use Screening Tools
- What Doctors Ask After a Positive Screen
- Drug Testing and Toxicology Screens
- How Results Guide Next Steps
- Privacy, Safety, and Preparing for the Visit
What Drug Use Screening Means
Drug use screening is a first-step check for substance use patterns that may affect health, safety, mood, thinking, or daily functioning. It usually involves brief, standardized questions rather than a lab test.
Clinicians use the term “unhealthy drug use” broadly. It can include use of illegal drugs, use of prescription medications in a way other than prescribed, or use that creates medical, psychological, legal, work, school, or relationship problems. It does not automatically mean addiction. Some people screen positive because they used cannabis occasionally, took someone else’s pain medication once, used stimulants to stay awake, or mixed sedatives with alcohol. Others may have a more serious pattern that meets criteria for a substance use disorder.
A useful distinction is screening versus diagnosis. Screening asks, “Is there enough concern to look more closely?” Diagnosis asks, “Does this person meet clinical criteria for a specific disorder?” That difference matters because a positive screen is not a final judgment. It is a prompt for a more careful conversation. For a broader explanation of this distinction in mental health care, see screening versus diagnosis.
Doctors may screen for several substance categories, including:
- Cannabis
- Opioids, including heroin, fentanyl, and nonmedical use of prescription pain medicines
- Stimulants, such as cocaine, methamphetamine, and nonmedical use of ADHD medications
- Sedatives, sleeping pills, or anti-anxiety medicines used outside the prescription plan
- Hallucinogens, inhalants, and other substances
- Tobacco, nicotine, and alcohol, depending on the tool used
Alcohol screening is often handled with separate tools because alcohol has its own risk thresholds and screening questionnaires. When alcohol use is part of the concern, clinicians may use approaches described in alcohol use screening or compare tools such as AUDIT-C and CAGE.
Drug use screening is also different from asking, “Are you addicted?” Many people who would answer no to that question still have medication interactions, overdose risk, withdrawal risk, impaired driving risk, worsening anxiety, or sleep disruption related to substance use. Good screening avoids loaded language and asks specific questions about what was used, how often, how recently, and in what context.
In mental health and cognitive evaluations, screening helps prevent missed explanations. For example, heavy cannabis use may contribute to memory and motivation problems in some people. Stimulant use can worsen panic, insomnia, paranoia, or mood swings. Sedatives and opioids can slow thinking, impair coordination, and raise overdose risk, especially when combined with alcohol or other depressants. Withdrawal from some substances can cause anxiety, agitation, tremor, insomnia, confusion, or seizures.
The main purpose is not to catch someone doing something wrong. It is to make care safer and more accurate.
When Doctors Screen for Drug Use
Doctors may screen for drug use routinely in primary care, during mental health visits, or when symptoms suggest that substance use could be affecting the clinical picture. Screening is most useful when the clinic can provide brief advice, follow-up assessment, harm-reduction counseling, or referral to treatment when needed.
Routine screening is common in primary care because many people do not volunteer substance use unless asked in a normal, matter-of-fact way. A clinician may include drug use questions alongside questions about sleep, mood, medications, alcohol, tobacco, sexual health, and safety. This makes the conversation less stigmatizing and helps identify risks earlier.
Screening is especially relevant when someone has symptoms that overlap with intoxication, withdrawal, or substance-related effects. Examples include sudden mood changes, panic attacks, insomnia, poor concentration, memory problems, hallucinations, paranoia, unexplained falls, fainting, chest pain, seizures, or repeated emergency visits. In these cases, substance use screening may be part of a broader mental health or neurological evaluation, not a standalone judgment about behavior.
Drug use screening may also be used before or during treatment with medications that can interact with substances. This includes opioids for pain, benzodiazepines, sleep medicines, stimulants, some psychiatric medications, and certain neurologic medications. A clinician needs to know about substance use to reduce overdose risk, avoid dangerous combinations, and interpret side effects correctly.
Common settings include:
- Primary care checkups
- Emergency departments and urgent care
- Psychiatry, psychology, and counseling visits
- Neurology or cognitive symptom evaluations
- Pregnancy and postpartum care
- Pain management visits
- Preoperative assessments
- School or adolescent health visits
- Addiction medicine clinics
- Occupational or legal settings, when required by policy or court order
The approach should change depending on the context. In a routine primary care visit, screening may be a short questionnaire. In an emergency setting, the immediate concern may be overdose, intoxication, withdrawal, delirium, injury, or psychosis. In a mental health evaluation, the clinician may ask more detailed questions about timing: whether anxiety, depression, mania-like symptoms, hallucinations, or cognitive changes began before substance use, during use, after stopping, or during withdrawal.
For people with concentration, mood, sleep, or memory concerns, substance use screening is often one piece of a larger assessment. It may be considered alongside depression screening, anxiety screening, sleep evaluation, medication review, lab work, and cognitive testing. A general primary care screening process is described in mental health screening in primary care.
Pregnancy is a special situation because screening can have medical benefits but may also carry social or legal consequences depending on local rules. A careful clinician should explain what is being asked, why it matters, how results may be documented, what confidentiality protections apply, and whether any reporting requirements exist. Informed consent and nonpunitive support are especially important.
Adolescent screening also requires careful handling. Teenagers may be more honest when they understand confidentiality limits, such as situations involving immediate danger, abuse, impaired driving, or serious risk to self or others. Clinicians should explain those limits clearly before asking sensitive questions.
Common Drug Use Screening Tools
Standardized screening tools help clinicians ask consistent questions instead of relying on vague impressions. The right tool depends on the person’s age, setting, substances of concern, time available, and whether the goal is quick screening or a more detailed risk assessment.
A screening tool may be self-administered on paper, completed through a patient portal, answered on a tablet in the clinic, or asked verbally by a clinician. Many people answer more honestly when they can complete sensitive questions privately, but some patients prefer a conversation, especially if they have questions about what counts as nonmedical use.
Several tools may be used in medical and behavioral health settings:
| Tool | What it is often used for | What a positive result means |
|---|---|---|
| Single-question drug screen | A very brief first question about nonmedical drug use, often in the past year | More questions are needed to understand frequency, substance type, and risk |
| DAST | A drug abuse screening questionnaire used to estimate problems related to drug use | The score may suggest low, moderate, substantial, or severe concern depending on the version and scoring |
| TAPS | A tobacco, alcohol, prescription medication, and other substance screening and assessment approach | Positive responses can lead to substance-specific follow-up questions |
| ASSIST | A broader substance involvement tool covering several substance categories | Scores can help estimate risk level and guide brief intervention or referral |
| CRAFFT | A screening tool commonly used with adolescents | A positive result suggests the need for a confidential, developmentally appropriate follow-up assessment |
The DAST, or Drug Abuse Screening Test, is one of the better-known tools. It asks about problems related to drug use, such as difficulty stopping, blackouts, guilt, family complaints, neglecting responsibilities, withdrawal symptoms, or medical problems. A higher score does not by itself diagnose a substance use disorder, but it can show that drug use deserves more careful evaluation. More detail is available in DAST screening results.
The TAPS tool is designed to combine brief screening with follow-up assessment for tobacco, alcohol, prescription medication misuse, and other substance use. It can be useful in busy medical settings because it starts broad and then narrows to the substances that matter for that person.
The ASSIST is broader and asks about lifetime use, recent use, cravings, health or social problems, failure to meet expectations, concern from others, attempts to cut down, and injection use. It can help clinicians sort lower-risk use from patterns that may need a brief intervention, more structured assessment, or specialty care.
No questionnaire is perfect. People may underreport because of stigma, fear of consequences, memory gaps, or uncertainty about what counts. Others may overinterpret a question and report prescribed medication use even when they are taking it exactly as directed. Good clinicians clarify the wording. For example, “nonmedical use” of a prescription medication usually means taking it without a prescription, taking more than prescribed, taking it more often than prescribed, taking it for a different reason, or using someone else’s medication.
A positive screen should lead to a respectful conversation, not an automatic label. A negative screen can also be incomplete if symptoms strongly suggest intoxication, withdrawal, or medication interaction. In those cases, clinicians may ask again in a more specific way, review medications, speak with permission to family or caregivers, or consider medical testing when clinically necessary.
What Doctors Ask After a Positive Screen
After a positive screen, doctors usually ask more detailed questions to understand risk, severity, safety, and whether the person may have a substance use disorder. This follow-up assessment is where the clinical picture becomes clearer.
The clinician will usually start by identifying the substance or substances involved. This matters because cannabis, opioids, stimulants, sedatives, hallucinogens, inhalants, and prescription medications can have very different health effects and risks. The same person may also use more than one substance, and combinations can be more dangerous than any one substance alone.
Follow-up questions often cover:
- What substance was used
- How often it is used
- How much is used
- How it is taken, such as swallowed, smoked, vaped, snorted, or injected
- When it was last used
- Whether use has increased over time
- Whether the person has tried to cut down
- Whether cravings occur
- Whether use affects work, school, parenting, driving, relationships, or finances
- Whether use continues despite physical or mental health problems
- Whether tolerance or withdrawal symptoms are present
- Whether there has been overdose, injury, risky sexual behavior, or legal trouble
- Whether the person uses alone or in unsafe settings
- Whether fentanyl exposure is possible
- Whether needles or other equipment are shared
Doctors also ask about mental health symptoms because substance use and psychiatric symptoms can influence each other. Depression, anxiety, trauma symptoms, ADHD, bipolar symptoms, psychosis, and sleep disorders can all affect substance use patterns. At the same time, substances can mimic or worsen psychiatric symptoms. For example, stimulant use can look like severe anxiety, mania, or psychosis. Sedatives can worsen depression, memory problems, and falls. Cannabis can worsen panic, dissociation, or paranoia in some people.
When the main concern is mood, hallucinations, delusions, or disorganized thinking, substance use screening may be part of a broader psychosis evaluation. The clinician may ask whether symptoms happen only during intoxication or withdrawal, whether they persist during periods of abstinence, and whether there is a personal or family history of mental illness.
Assessment also includes strengths and supports. A doctor may ask who the person trusts, whether they have stable housing, whether they feel safe, whether they have transportation, whether they can attend appointments, and whether they have used treatment before. These details shape the next step. A person with mild risk and strong motivation may benefit from brief counseling and follow-up. Someone with opioid use disorder, repeated overdose, injection-related infection, severe withdrawal, or unstable housing may need faster linkage to medication treatment, harm-reduction services, or specialty care.
Clinicians may also assess readiness to change. This should not be used to deny care. A person who is not ready to stop all use may still be ready to reduce harm, avoid mixing substances, carry naloxone, use fentanyl test strips where legal and available, avoid driving while impaired, use sterile injection equipment, or make a safety plan. Good care meets the person at the point where practical change is possible.
A substance use disorder diagnosis is usually based on a pattern of symptoms, not a single episode. Clinicians look for impaired control, social impairment, risky use, tolerance, and withdrawal, while considering whether tolerance or withdrawal is expected from prescribed medication taken as directed. Diagnosis should be made carefully because it can affect treatment, documentation, insurance, employment concerns, and trust.
Drug Testing and Toxicology Screens
Drug testing can detect recent exposure to certain substances, but it is not the same as drug use screening and cannot diagnose a substance use disorder by itself. Questionnaires and clinical interviews usually provide more useful information about patterns, consequences, and severity.
Toxicology testing may involve urine, blood, saliva, hair, or breath testing. Urine testing is the most common in outpatient medical settings because it is relatively easy to collect and can detect many substances after recent use. Blood testing is more often used when clinicians need information about current intoxication, poisoning, emergency care, or legal-medical questions. Saliva testing may detect more recent use for some substances. Hair testing can reflect a longer window but is not usually the best tool for routine clinical screening.
A key limitation is the detection window. Many substances are detectable only for a short period, and the window varies by the substance, amount, frequency of use, metabolism, test type, and cutoff level. A positive result may show exposure but not impairment, addiction, timing with precision, or whether the person has a substance use disorder. A negative result does not always rule out use, especially if the substance was not included in the test panel, the use occurred outside the detection window, or the sample was diluted.
False positives and false negatives can occur. Some screening immunoassays are broad first-pass tests and may need confirmatory testing, such as gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry, when results carry serious consequences. This is especially important in pain management, pregnancy, employment-related situations, legal settings, child welfare contexts, or when a result conflicts with the person’s report.
Doctors may order toxicology testing when it will change medical care. Examples include suspected overdose, unexplained confusion, severe agitation, seizure, psychosis, chest pain after possible stimulant use, medication safety monitoring, or assessment before prescribing certain controlled substances. In mental health and brain symptom workups, toxicology may help identify intoxication, withdrawal, or medication interactions that could be contributing to symptoms. This is discussed more specifically in toxicology screening for mental health and brain symptoms.
Testing should be explained clearly. Patients should know what is being tested, why it is being tested, who will see the result, whether confirmatory testing is available, and what may happen after a positive result. In routine care, surprise testing can damage trust. In emergency care, testing may be done when a person is too ill, confused, unconscious, or unsafe to provide a reliable history, but results still need careful interpretation.
The most helpful approach is to combine information. A clinician may consider the person’s symptoms, vital signs, medication list, screening questionnaire, clinical interview, physical exam, mental status exam, and lab results together. A urine result alone should not outweigh a thoughtful assessment.
Drug testing can also miss the most clinically important issue. For example, a standard panel may not detect some synthetic opioids, newer benzodiazepines, designer stimulants, or certain cannabis products. A person may be at high overdose risk even if a routine test does not show every substance involved. This is one reason doctors should not rely on toxicology as the only screening method.
How Results Guide Next Steps
Screening results guide the next step by estimating risk and matching support to the person’s needs. The response may range from brief advice to urgent medical care, depending on severity and safety.
A low-risk result may lead to simple education. The clinician may discuss avoiding impaired driving, not mixing substances with alcohol or sedatives, medication interactions, sleep effects, and warning signs that should prompt follow-up. If the person uses cannabis, for example, the conversation may focus on frequency, potency, anxiety or memory effects, driving, pregnancy considerations, and whether use is interfering with goals.
A moderate-risk result often leads to brief intervention. This is a focused conversation that may include feedback, motivational interviewing, harm-reduction planning, and a specific follow-up plan. The goal may be to reduce use, stop a risky combination, avoid using alone, switch to safer practices, or consider treatment. Brief interventions work best when they are collaborative rather than confrontational.
A high-risk result or likely substance use disorder calls for a fuller assessment and treatment planning. Depending on the substance and severity, next steps may include:
- Referral to addiction medicine, psychiatry, therapy, or an intensive outpatient program
- Medication treatment for opioid use disorder, such as buprenorphine or methadone through appropriate programs
- Medication treatment for alcohol use disorder when alcohol is involved
- Withdrawal management or medically supervised detoxification when stopping suddenly could be dangerous
- Naloxone prescribing and overdose prevention education
- Infectious disease screening when injection use is present
- Mental health evaluation for depression, anxiety, trauma, psychosis, or suicide risk
- Follow-up visits to monitor symptoms, safety, and goals
Not every substance has the same treatment options. Opioid use disorder has effective medications that reduce overdose risk and support recovery. Alcohol use disorder also has medication options. Stimulant use disorder is often treated with behavioral approaches, contingency management where available, and treatment of co-occurring mental health conditions. Cannabis use disorder may involve behavioral therapy, sleep support, anxiety treatment, and structured reduction plans.
If a screen is positive during a mental health evaluation, the clinician may also decide whether symptoms are substance-induced, independent, or both. This distinction can take time. A person may have depression that predates substance use and also worsens during withdrawal. Another person may have panic attacks only after stimulant use. Someone else may have psychosis that persists after intoxication has resolved. Careful timing, collateral information when appropriate, and follow-up are often more useful than a single visit.
A positive screen should not automatically lead to abrupt medication discontinuation. For example, if a patient taking prescribed opioids or benzodiazepines screens positive for other substance use, the clinician should assess risk and safety, but sudden stoppage can cause harm in some situations. Safer care usually involves discussion, risk mitigation, closer monitoring, alternative treatments, taper planning when appropriate, and referral if needed.
The most urgent next steps are medical, not administrative. Emergency evaluation is needed for possible overdose, severe withdrawal, suicidal thoughts with intent, violent impulses, severe confusion, chest pain after stimulant use, seizure, severe dehydration, pregnancy-related emergency symptoms, or psychosis with unsafe behavior. A broader safety-focused guide is available in when to go to the ER for mental health or neurological symptoms.
For less urgent but meaningful concerns, follow-up matters. A clinician may repeat screening after a few weeks or months, track use patterns, monitor mood and sleep, review medications, and adjust the care plan. Screening is most valuable when it becomes the start of care, not the end of the conversation.
Privacy, Safety, and Preparing for the Visit
Patients should expect drug use screening to be handled respectfully, privately, and with clear explanation of confidentiality limits. Honest answers usually help doctors provide safer care, but it is reasonable to ask how information will be used and documented.
Confidentiality rules vary by location, age, setting, and the purpose of screening. In ordinary medical care, substance use information is protected health information, but there may be exceptions involving immediate danger, abuse or neglect, impaired driving risk, court orders, workplace testing, pregnancy-related reporting laws in some jurisdictions, or insurance and medical record access. Adolescents should be told what can remain confidential and what cannot. Pregnant patients should be informed about possible reporting consequences before screening or testing whenever possible.
Before the visit, it can help to write down a clear, factual summary. This is especially useful if anxiety, shame, memory problems, or withdrawal symptoms make it hard to talk. Include:
- Substances used, including cannabis, opioids, stimulants, sedatives, inhalants, and nonmedical prescription medications
- Frequency and amount, as accurately as possible
- Last use
- Any recent change in use
- Prescribed medications, supplements, and over-the-counter drugs
- Alcohol use, if relevant
- Past overdose, withdrawal, seizures, blackouts, or injuries
- Attempts to cut down or stop
- Mental health symptoms and when they started
- Pregnancy status, if relevant
- Main goal for the visit, such as “I want to stop,” “I want to reduce harm,” “I am worried about withdrawal,” or “I need help understanding whether this is affecting my mood”
It is also appropriate to ask direct questions, such as:
- “Is this a screening questionnaire or a diagnostic evaluation?”
- “Will you order a drug test, or are you asking screening questions only?”
- “What happens if my screen is positive?”
- “Will this go in my medical record?”
- “Are there any reporting requirements I should understand?”
- “Can you help with treatment here, or would you refer me elsewhere?”
- “What should I do if I have withdrawal symptoms?”
- “Should I have naloxone?”
The best clinical conversations are specific and nonjudgmental. Instead of saying only “I use sometimes,” it is more useful to say, “I use cannabis most nights for sleep,” “I took oxycodone from a friend twice this month,” “I use cocaine on weekends and had chest tightness once,” or “I take extra alprazolam when I panic.” These details help the clinician identify real risks.
Safety planning may be part of the visit even if the person is not ready for treatment. For opioid risk, that may include naloxone, not using alone, avoiding sedative combinations, and knowing overdose signs. For injection use, it may include sterile supplies, hepatitis and HIV testing, wound care, and vaccination where appropriate. For stimulant use, it may include warning signs such as chest pain, severe headache, overheating, paranoia, or agitation. For sedatives or heavy alcohol use, it may include avoiding sudden unsupervised stopping because withdrawal can be dangerous.
A drug use screen can feel uncomfortable, but a well-run assessment should make care more accurate and less risky. The goal is to understand the whole picture: symptoms, substances, medications, mental health, physical health, safety, and the person’s own priorities. When doctors ask clearly and respond without judgment, screening can become a practical doorway to safer treatment, better diagnosis, and support that fits the person’s situation.
References
- Substance Use Screening, Risk Assessment, and Use Disorder Diagnosis in Adults. 2024 (Guideline)
- Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement. 2020 (Recommendation Statement)
- Implementing Recommended Mental Health and Substance Use Screening and Counseling Interventions in Primary Care Settings for Children and Adolescents. 2025 (Systematic Review)
- Identifying available substance use disorder screening tests feasible for use in primary care: A systematic review. 2024 (Systematic Review)
- Evidence-Based Assessment of Substance Use Disorder. 2024 (Review)
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. 2022 (Guideline)
Disclaimer
This article is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Drug use, withdrawal, overdose risk, pregnancy, severe mental health symptoms, and medication interactions should be discussed with a qualified healthcare professional. Seek urgent medical help for suspected overdose, severe withdrawal, chest pain, seizures, severe confusion, psychosis with unsafe behavior, or suicidal thoughts.
Please share this article on Facebook, X (formerly Twitter), or your preferred platform to help others understand how drug use screening works in medical and mental health care.
